2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 680

Development and Preliminary Validation of the Computed Tomography Sacroiliac Structural Score for Assessment of Structural Lesions in Axial Spondyloarthritis
Abstract Number: 1370

Development and Validation of a Composite Disease Activity Score for Juvenile Dermatomyositis
Abstract Number: 1298

Development and Validation of Berlin and Sparcc MRI Sacroiliac Joint Scoring Methods for the Semi-Axial Scan Plan
Abstract Number: 1945

Development and Validation of Case-Finding Algorithms for the Identification of Patients with ANCA-Associated Vasculitis and Large-Vessel Vasculitis in Healthcare Administrative Databases
Abstract Number: 3141

Development of a Glucocorticoid Toxicity Index Using Multi-Criteria Decision Analysis
Abstract Number: 3076

Development of a Matrix-Binding Interlukin-1 Receptor Antagonist Fusion Protein for Extended Retention in the Joint Tissues
Abstract Number: 709

Development of a Novel Medication Adherence Prediction Model for Patients with Ankylosing Spondylitis Based on Results from a Global Clinical Study
Abstract Number: 1160

Development of a Shared Decision Making Tool for Osteoporosis Treatment
Abstract Number: 837

Development of a Skin-Specific Scleroderma Patient Reported Outcome Instrument
Abstract Number: 1156

Development of a Taxonomy of Patient Engagement in Health Research
Abstract Number: 2021

Development of an Item Bank on Disease and Treatment Associated Knowledge of Rheumatoid Arthritis to Improve Patient Engagement in Care
Abstract Number: 3117

Development of Autoimmune Diseases and Genetic Predisposition in Children with Neonatal Lupus and Their Unaffected Siblings
Abstract Number: 516

Development of RA Patient Preference Phenotypes
Abstract Number: 708

Development of Spondyloarthritis-Features in Patients with Chronic Back Pain over a One-Year Course: Data from the Spondyloarthritis Caught Early (SPACE)-Cohort
Abstract Number: 2089

Deviation of T and B Cell Subset and Its Association with Single Nucleotide Polymorphisms in Patients with Antiphospholipid Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].